SCHEMBL4704261

SCHEMBL4704261

CC(C)(C)C1CCc2nc3sc(C(N)=O)nc3cc2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 3/20 0.39
ANO1 Q5XXA6 2/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
TP53 P04637 4/20 0.39
POLB P06746 2/20 0.38
RORC P51449 1/20 0.38
RXFP1 Q9HBX9 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
PKM P14618 1/20 0.36
KMT2A Q03164 2/20 0.35
PDE4B Q07343 1/20 0.35
PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22690756 0.89 MAPT (0.41) MAPTKDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL29926217 0.89 MAPT (0.41) MAPTKDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL22690753 0.89 MAPT (0.41) MAPTKDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL22691455 0.89 MAPT (0.41) MAPTKDM4EHPGDSMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL5996085 0.88 MAPT (0.41) MAPTKDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL5996075 0.88 TP53 (0.41) MAPTKDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL22699236 0.84 TP53 (0.42) MAPTKDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL22699235 0.84 TP53 (0.42) MAPTKDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL22699209 0.84 MAPT (0.40) MAPTKDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL4705292 0.84 TP53 (0.42) MAPTKDM4EHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871776-A2 FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2008-01-02 EP disclosed
US-20060247320-A1 Compounds for inhibiting KSP kinesin activity SCHERING CORPORATION 2006-11-02 US disclosed
WO-2006098961-A2 FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247320-A1 Compounds for inhibiting KSP kinesin activity KIFC1, KIF5B, KIF2C MAPT 434/4885KDM4E 501/4885HPGD 4077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.